Benitec Biopharma's EPS (Basic) for the
three
months ended in Dec. 2023 was $-2.64.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.95.
During the past 3 years, the average EPS without NRIGrowth Rate was -19.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 11 years, Benitec Biopharma's highest 3-Year average EPS without NRI Growth Rate was 59.60% per year. The lowest was -19.90% per year. And the median was 21.30% per year.
Benitec Biopharma EPS (Diluted) Historical Data
The historical data trend for Benitec Biopharma's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Benitec Biopharma's EPS (Diluted)
For the Biotechnology subindustry, Benitec Biopharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benitec Biopharma's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benitec Biopharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where Benitec Biopharma's PE Ratio falls into.
Benitec Biopharma EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Benitec Biopharma's Diluted EPS for the fiscal year that ended in Jun. 2023 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Benitec Biopharma EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Benitec Biopharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Benitec Biopharma (Benitec Biopharma) Business Description
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BNTC has been successfully added to your 